About 700 reports

  • A: CAUSES OF HEPATITIS B
  • Hepatitis B Drugs Pipeline

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Hepatitis B Treatment Market by Type (Therapeutics and Vaccines), By End-User (Male and Female) for...

  • Hepatitis
  • World
  • Market Size
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Hepatitis C
  • Hepatitis B

About Hepatitis B and Hepatitis C Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot...

  • Hepatitis
  • World
  • Market Size
  • QIAGEN N.V.
  • Roche Group
  • HEPATITIS DRUGS
  • Hepatitis Drugs Sales Volumes

China’s demand for Hepatitis Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...

  • Hepatitis
  • China
  • Demand
  • Beijing Union Pharmaceutical Co., Ltd.
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.
  • TREATMENT GUIDELINES FOR HEPATITIS C
  • LEADING TREATMENTS FOR HEPATITIS C, 2016

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), Hepatocellular...

  • Hepatitis
  • Market Size
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • depicts the treatment patterns of hepatitis C in India. The hepatitis C prevalence
  • depicts the prevalence population of hepatitis C in South Korea. The prevalence

Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape Summary Recent years have seen a revolution in hepatitis C therapeutic development, and the treatment algorithms have rapidly shifted...

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group

Hepatitis C Global Clinical Trials Review, H##, 2017 Table of Contents ## List of Tables ## List of Figures ## Report Guidance ## GlobalData Clinical Trials Report Coverage ## Clinical Trials by Region ## Clinical Trials and Average Enrollment by Country ## Top Five Countries Contributing to Clinic

  • Clinical Trial
  • Drug Discovery And Development
  • Hepatitis
  • Pathology
  • World
  • HEPATITIS DRUGS
  • Other Hepatitis Drugs

This study focuses on China’s Hepatitis Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is...

  • Hepatitis
  • China
  • Beijing Union Pharmaceutical Co., Ltd.
  • Livzon Group
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.
  • Products in Clinical Development for Hepatitis C
  • Promising Drugs in Development for Hepatitis C

Hepatitis C: Competitive Landscape to 2026 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV), a small enveloped RNA virus.If left untreated, chronic infection can result in fibrosis, cirrhosis, hepatocellular carcinoma, and eventually death. HCV is spread primarily...

  • Hepatitis
  • China
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • 6.1 Complexity of Signaling Networks in Hepatitis C
  • HEPATITIS C THERAPEUTICS MARKET, GLOBAL, CO-

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C market has witnessed a historically rare market penetration in terms of the breadth and quality of several strongly innovative and very competitive...

  • Hepatitis
  • World
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Hepatitis Drugs Sales Volumes
  • Other Hepatitis Drugs

This study focuses on China’s Hepatitis Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...

  • Hepatitis
  • China
  • Demand
  • Beijing Union Pharmaceutical Co., Ltd.
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.
  • HEPATITIS C VIRUS GENOTYPE DESCRIPTION
  • 3.1 BIBLIOGRAPHY

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025 Summary Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV) (CDC, 2015; WHO, 2015). HCV can cause both acute and chronic hepatitis infection (WHO, 2015). According to the World Health Organization (WHO), an estimated 130–150...

  • Hepatitis
  • Brazil
  • China
  • United States
  • Forecast

Hepatitis B Diagnostic Tests Market: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027) ##.

  • Hepatitis
  • In Vitro Diagnostic Reagent
  • In Vitro Diagnostics
  • Pathology
  • Forecast
  • TREATMENT GUIDELINES FOR CHRONIC HEPATITIS B
  • PHASES OF CHRONIC HEPATITIS B INFECTION

PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the...

  • Hepatitis
  • Market Size
  • Gilead Sciences, Inc.
  • Novartis AG
  • Roche Group

The 2019-2024 World Outlook for Hepatitis C Virus (HCV) Therapeutics ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Hepatitis
  • Pathology
  • World
  • Demand

Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed.

  • Hepatitis
  • Europe
  • Japan
  • United States
  • Demand
  • HEPATITIS
  • PREVALENCE DATA OF HEPATITIS C IN EUROPE

About viral hepatitis and retrovirus diagnostic tests Diagnostics tests for viral hepatitis and retrovirus help in screening, diagnosing, and managing diseases in humans. The tests are usually performed in the laboratory under controlled environment. In hepatitis and retrovirus infections, the diagnostic tests provide a valuable health...

  • Hepatitis
  • World
  • Alere Inc.
  • DiaSorin S.p.A.
  • Roche Group

It is one of the five known human hepatitis viruses (A, B, C, D, and E).

  • Hepatitis
  • Pathology
  • APAC
  • World
  • Forecast

Global Hepatitis Drug Market & Clinical Trials Insight 2023 ##.

  • Hepatitis
  • Pathology
  • World
  • Forecast

NPS+ Hepatitis C Virus (HCV) Infection US [2018] ##.

  • Hepatitis
  • Infectious Disease
  • Pathology
  • United States

NPS+ Hepatitis C Virus (HCV)Infection (EU##) [2018] ##.

  • Healthcare
  • Hepatitis
  • Pathology

## North America Hepatitis Diagnostics Market, by Test Type, 2014 - 2025 (USD Million) TABLE ## North America Hepatitis Diagnostics Market, by Blood Tests Market, 2014 - 2025 (USD Million) TABLE ## U. S. hepatitis diagnostics market, by test type, 2014 - 2025 (USD Mil

  • Diagnostics
  • Hepatitis
  • United States
  • Forecast
  • Market Size

Hepatitis Therapeutics Market Size, Share And Trend Analysis By Disease Type By Region And Segment Forecasts, 2018 - 2025 Chapter ##.

  • Hepatitis
  • Pathology
  • Therapy
  • United States
  • Forecast
  • PHASES OF CHRONIC HEPATITIS B INFECTION
  • TREATMENT GUIDELINES FOR CHRONIC HEPATITIS B

Hepatitis B Virus (HBV) Therapeutics - US Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains...

  • Hepatitis
  • United States
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.

Emerging Diagnostic Technologies ##.

  • Diagnostics
  • Hepatitis
  • Pathology
  • Forecast
  • Market Size
  • TREATMENT GUIDELINES FOR CHRONIC HEPATITIS B
  • PHASES OF CHRONIC HEPATITIS B INFECTION

Hepatitis B Virus (HBV) Therapeutics - China Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains...

  • Hepatitis
  • China
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • 3.4.2 Complications of Chronic Hepatitis B
  • PHASES OF CHRONIC HEPATITIS B INFECTION

Hepatitis B Virus (HBV) Therapeutics - Japan Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains...

  • Hepatitis
  • Japan
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.

## North America Hepatitis Diagnostics Market, by Test Type, 2014 - 2025 (USD Million) TABLE ## North America Hepatitis Diagnostics Market, by Blood Tests Market, 2014 - 2025 (USD Million) TABLE ## U. S. hepatitis diagnostics market, by test type, 2014 - 2025 (USD Mil

  • Hepatitis
  • Pathology
  • United States
  • Forecast
  • Market Size

Hepatitis C

4546 5000 3864
  • TREATMENT: HEPATITIS C
  • Treatment: Hepatitis C

The $21bn hepatitis C market is expected to undergo a net decline from 2016 as new entrants intensify pricing competition and patient numbers are exhausted from the early 2020s. This report addresses the following questions: - To what extent will the launch of Merck & Co’s Zepatier at a discounted price affect sales of...

  • Hepatitis
  • European Union
  • Japan
  • North America
  • United States

Hepatitis B Phase ## Clinical Trials, 2016 ##.

  • Hepatitis
  • France
  • Germany
  • United States
  • Market Shares

Hepatitis C Phase ## Clinical Trials, 2016 ##.

  • Hepatitis
  • France
  • Germany
  • United States
  • Market Shares